Myeloma bone disease: pathogenesis and treatment

Area of Science:

• Oncology
• Bone Biology
• Pharmacology

Background:

• Multiple myeloma (MM) frequently causes osteolytic bone disease (OBD), leading to skeleton-related events (SREs) like fractures and pain.
• These events significantly impair patient quality of life and survival.
• OBD in MM results from disrupted bone remodeling, characterized by increased osteoclast activity and inhibited osteoblast function.

Purpose of the Study:

• To review the impact of osteolytic bone disease in multiple myeloma.
• To highlight the role of novel therapeutic agents in managing bone complications.
• To discuss future strategies for improving patient outcomes through targeted bone treatments.

Main Methods:

• Literature review of studies on multiple myeloma bone disease.
• Analysis of current and emerging therapeutic agents targeting bone remodeling.
• Synthesis of information on the impact of SREs on MM patients.

Main Results:

• Osteolytic bone disease affects nearly 90% of MM patients, causing significant morbidity.
• Novel agents targeting osteoclast inhibition or osteoblast stimulation are under investigation.
• Bisphosphonates are established treatments, but new agents offer additional therapeutic potential.

Conclusions:

• Effective management of OBD and SREs is crucial for improving quality of life and survival in MM.
• Novel agents targeting bone remodeling represent a promising therapeutic avenue.
• Combination or sequential therapies may enhance antitumor activity and patient outcomes.